PharmaVigilant Unveils I-Builder 2.0 to Decrease Study Build Time and Ease Technology Transfers for Sponsors
New Product Empowers Sponsors to Build and Transfer Studies in Less Than Four Weeks
WESTBOROUGH, MA PharmaVigilant, a clinical trial technology provider, today unveils an enhanced study-building solution that will ease the study build process and technology transfer for sponsors with their enhanced I-Builder 2.0. I-Builder 2.0 provides the industry's most intuitive and innovative user interface for building EDC studies. I-Builder can support multiple users for building all phases of clinical research studies from simple studies to global, multi-center or adaptive study designs.
"The study design serves as the solid foundation for successful program execution. Studies not based on the proper architecture suffer from cracks and data issues that result in costly delays," said James DeSanti, Founder and Chief Executive Officer, PharmaVigilant. "With I-Builder 2.0, PharmaVigilant is offering an extremely powerful technology that makes it simple for sponsors to build innovative and adaptive study designs in record time, using fewer internal resources than with other systems on the market. And the new interface will ensure that sponsors can integrate I-Builder into their organizations with minimal training, and little need for any on-going support."
With the introduction of I-Builder 2.0, PharmaVigilant is leading the industry by offering technology that enables sponsors to build studies in record time. I-Builder is a Web based, thin client application that can support multiple users for their global study design needs, and offers a complete study builder module enabling sponsors to build trials from simple to complex adaptive trials for Phase I-IV.
PharmaVigilant is demystifying the clinical trial process by offering sponsors complete visibility and access into the collection and management of their clinical trial data. In addition to I-Builder 2.0, the Company offers a full suite of clinical trial technology offerings including Electronic Data Capture (EDC), data warehousing, Electronic Trial Master File System (eTMF), Remote Source Document Verification (rSDV), study administration and an automated site payment system. PharmaVigilant focuses on Phase I-IV clinical trials, registries and other post-marketing studies. The technology has supported more than 200,000 patients in 14 countries across North America, Europe, Asia and Australia and continues to expand rapidly.
Based in Westborough, Mass., PharmaVigilant is a technology company founded in 2005 to demystify the clinical trial process for biopharmaceutical companies. Its full suite of patient-based technology automates the collection and management clinical trial data and most importantly puts that data in the sponsors' hands when and how they want it. Sponsors rely on PharmaVigilant to ease the regulatory and FDA submission and approval process and ultimately go-to-market more quickly with top quality drugs. For more information, visit www.pharmavigilant.com.